Changes in the level of perforin and its transcript during effector and target cell interactions

Perforin is a cytoplasmic granule protein expressed in cytotoxic lymphocytes, and is capable of lysing target cells. This protein is induced as cytotoxic T cells are activated, and the mRNA expression is modulated by various stimulators. These observations suggest possible changes in the level of perforin transcripts and protein when killer lymphocytes meet specific target cells leading to target cell death. To address this question, we examined three murine T-cell clones and primary human NK cells in perforin expression. When the cytotoxic lymphocytes were exposed to sensitive targets, perforin mRNA disappeared within 5 to 30 min and appeared within an hour thereafter. Among the murine T cell clones, L3 and OE4 showed two phases of mRNA decrease while human NK cells and the third murine T cell clone, AB.1, showed only one phase of mRNA loss during a 240 min period. The data indicate that when cytotoxic lymphocytes receive signals from a sensitive target, the cells rapidly degrade previously accumulated perforin mRNA and synthesize new transcripts. Interestingly, heat shock protein 70 mRNA was induced as the perforin mRNA levels recovered, while P55 Il-2 receptor mRNA was downregulated within 5 min after exposure to targets. The perforin protein level also rapidly decreased immediately after the interaction with the target, followed by a recovery, and then another decrease as seen in primary human NK cells, OE4 and L3 cells. However, in the AB.1 clone, no change in perforin content was detectable, despite the loss of perforin mRNA. Since all three T-cell clones had comparable levels of killing of approx. 45% by 4 h, the AB.1 effector must receive an adequate signal to kill the target cells. These observations suggest that the AB.1 may be less dependent on perforin as a mechanism for killing.This work was supported by U.S. Public Health Service (NIH) grants MAI-28175, DE10525 and KllDE00310. Kack-K. Kim is supported by a fund from the Cancer Research Center, Seoul National University, Seoul, Korea (KOSEF-SRC-56-CRC-21). The authors wish to thank Dr. Ko Okumura for his generous gift of antiperforin monoclonal antibody P1-8, Dr. Feng Zhou for help with the Image analyzer, Dan Wood and Dr. Karen Pollok for editorial assistance, and Ms. Audrey Carson for typing the manuscript